<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390933</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-00768</org_study_id>
    <nct_id>NCT03390933</nct_id>
  </id_info>
  <brief_title>Identifying and Treating Depression in Hemodialysis Patients</brief_title>
  <official_title>Using Latent Variables and Directly Observed Treatment to Improve the Diagnosis and Management of Depression Among Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is present in about 20-30% of hemodialysis patients and is associated with
      morbidity and mortality. However, depression is inadequately diagnosed and treated among
      dialysis patients. This is due in part to the overlap between depressive symptoms (e.g.
      appetite change, trouble sleeping, feeling tired) and symptoms related to persistent
      metabolic derangements in hemodialysis patients (e.g. nausea, nocturnal cramps, feeling
      washed out after treatment). The overlap between depressive symptoms and dialysis-related
      complications makes it difficult to diagnose and therefore to treat depression. In addition,
      prescription of antidepressant medication may increase an already high pill burden and result
      in poor adherence. Moreover, the evidence base to guide depression treatment among
      hemodialysis patients is limited. In the investigators' previous work, they developed methods
      to use latent variables and structural equation modeling to isolate depressive symptoms.
      Other investigators have demonstrated that directly observed treatment enhances the
      effectiveness of tuberculosis and HIV treatment.

      Investigators now propose a cross-sectional study (Phase 1) followed by a single-arm clinical
      trial (Phase 2) at 17 dialysis facilities. The cross-sectional study will involve assessments
      of depressive symptoms (using the PHQ-9 screening instrument) as well as dialysis-related
      complications, anxiety, and quality of life (Quality of Life Questionnaire) in about 1083
      patients. Investigators will then use structural equation modeling to develop and validate a
      hemodialysis-specific PHQ-9 (hdPHQ-9) that will isolate depressive symptoms. The trial will
      involve 96 patients with confirmed depression who will be assigned to directly observed
      weekly antidepressant treatment with fluoxetine. The primary outcome of the trial will be
      remission of depression at 12 weeks. The trial results will also be used to compare the
      responsiveness of the PHQ-9 and the hdPHQ-9. Investigators anticipate that the hdPHQ-9 will
      be a valid and responsive instrument that will isolate depressive symptoms in hemodialysis
      patients and ultimately improve the screening and diagnosis of depression. Investigators also
      expect that directly observed weekly fluoxetine treatment will be an effective way to manage
      depression among hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is present in about 20-30% of hemodialysis patients and is associated with
      morbidity and mortality. However, depression is inadequately diagnosed and treated among
      dialysis patients. This is due in part to the overlap between depressive symptoms (e.g.
      appetite change, trouble sleeping, feeling tired) and symptoms related to persistent
      metabolic derangements in hemodialysis patients (e.g. nausea, nocturnal cramps, feeling
      washed out after treatment). The overlap between depressive symptoms and dialysis
      complications makes it difficult to diagnose and therefore to treat depression. In addition,
      prescription of antidepressant medication may increase an already high pill burden and result
      in poor adherence. Moreover, the evidence base to guide depression treatment among
      hemodialysis patients is limited. In the investigators' previous work, they developed methods
      to use latent variables and structural equation modeling to isolate depressive symptoms.
      Other investigators have demonstrated that directly observed treatment enhances the
      effectiveness of tuberculosis and HIV treatment.

      Investigators now propose a cross-sectional study (Phase 1) followed by a single-arm clinical
      trial (Phase 2) at 17 dialysis facilities. The cross-sectional study will involve assessments
      of depressive symptoms (using the PHQ-9 screening instrument) as well as dialysis-related
      complications, anxiety, and quality of life (Quality of Life Questionnaire) in about 1083
      patients. The investigators will then use structural equation modeling to develop and
      validate a hemodialysis-specific PHQ-9 (hdPHQ-9) that will isolate depressive symptoms. The
      trial will involve 96 patients with confirmed depression who will be assigned to directly
      observed weekly antidepressant treatment with fluoxetine. The primary outcome of the trial
      will be remission of depression at 12 weeks. The trial results will also be used to compare
      the responsiveness of the PHQ-9 and the hdPHQ-9.

      The investigators anticipate that the hdPHQ-9 will be a valid and responsive instrument that
      will isolate depressive symptoms from dialysis complications and ultimately improve the
      screening and diagnosis of depression. They also expect that directly observed weekly
      fluoxetine treatment will be an effective way to manage depression among hemodialysis
      patients.

      Innovative features of the proposed project include the use of latent variables to address
      overlap, administration of a long acting weekly antidepressant, and directly observed
      treatment. The project has the potential not only to improve the diagnosis and management of
      depression among hemodialysis patients but also to improve their morbidity and mortality.
      Furthermore, it may serve as a model for future studies to isolate symptoms among overlapping
      medical conditions.

      Aim A. To develop and validate a self-reported depression screening instrument that isolates
      depressive symptoms from hemodialysis-related complications.

      Hypothesis: A hemodialysis-specific PHQ-9 (hdPHQ-9) will isolate depressive symptoms from
      dialysis complications.

      Aim B. To determine the impact of directly observed weekly fluoxetine treatment on remission
      of depression among hemodialysis patients.

      Hypothesis: About half of patients who have directly observed fluoxetine treatment will have
      remission of depression.

      Aim C. To examine the responsiveness of the new depression screening instrument to depression
      treatment.

      Hypothesis: Fluoxetine treatment will be associated with larger improvements in hdPHQ-9
      scores than in PHQ-9 scores.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The cross-sectional study will involve assessments of depressive symptoms (PHQ-9) and quality of life for 1083 patients. These data will be used to address Aim A. The single arm trial will involve 96 patients with DSM5-confirmed depression.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To develop and validate a self-reported depression screening instrument that isolates depressive symptoms from hemodialysis-related complications.</measure>
    <time_frame>5 years</time_frame>
    <description>baseline scores on measures of depression (PHQ-9) baseline scores of dialysis complications (KDQOL) factor analysis of the nine PHQ-9 items structural equation modeling of overlap of depressive symptoms and dialysis complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the impact of directly observed weekly fluoxetine treatment on remission of depression among hemodialysis patients.</measure>
    <time_frame>5 years</time_frame>
    <description>remission of depression, defined as a week 12 PHQ-9 score of &lt;5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the responsiveness of the new depression screening instrument to depression treatment.</measure>
    <time_frame>5 years</time_frame>
    <description>change in hdPHQ-9 scores (delta hdPHQf)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Depression</condition>
  <condition>Hemodialysis-Induced Symptom</condition>
  <arm_group>
    <arm_group_label>Fluoxetine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.</description>
    <arm_group_label>Fluoxetine Group</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  currently on hemodialysis at a CDC dialysis unit

          -  English speaking

          -  able to provide informed consent

        Exclusion Criteria:

          -  on hemodialysis for less than 3 months

          -  comorbid psychotic, bipolar, substance use dependence, Alzheimer's or dementia

        Not eligible for Phase II (intervention) if currently on antidepressant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacqueline Dolata</last_name>
    <phone>216-778-1792</phone>
    <email>jdolata@metrohealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Dolata, MBA</last_name>
      <phone>216-778-1792</phone>
      <email>jdolata@metrohealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cohen SD, Norris L, Acquaviva K, Peterson RA, Kimmel PL. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2007 Nov;2(6):1332-42. Epub 2007 Oct 17. Review.</citation>
    <PMID>17942763</PMID>
  </reference>
  <reference>
    <citation>Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int. 2006 May;69(9):1662-8.</citation>
    <PMID>16598203</PMID>
  </reference>
  <reference>
    <citation>Watnick S, Wang PL, Demadura T, Ganzini L. Validation of 2 depression screening tools in dialysis patients. Am J Kidney Dis. 2005 Nov;46(5):919-24.</citation>
    <PMID>16253733</PMID>
  </reference>
  <reference>
    <citation>Cohen SD, Kimmel PL. Nutritional status, psychological issues and survival in hemodialysis patients. Contrib Nephrol. 2007;155:1-17. Review.</citation>
    <PMID>17369709</PMID>
  </reference>
  <reference>
    <citation>Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000 May;57(5):2093-8.</citation>
    <PMID>10792629</PMID>
  </reference>
  <reference>
    <citation>Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Verme D, Umana WO, Veis JH, Alleyne S, Cruz I. Behavioral compliance with dialysis prescription in hemodialysis patients. J Am Soc Nephrol. 1995 Apr;5(10):1826-34.</citation>
    <PMID>7787151</PMID>
  </reference>
  <reference>
    <citation>Lacson E Jr, Bruce L, Li NC, Mooney A, Maddux FW. Depressive affect and hospitalization risk in incident hemodialysis patients. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1713-9. doi: 10.2215/CJN.01340214. Epub 2014 Oct 2.</citation>
    <PMID>25278546</PMID>
  </reference>
  <reference>
    <citation>Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstr√∂m B, Saito A, Port FK. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int. 2004 Nov;66(5):2047-53. Erratum in: Kidney Int. 2004 Dec;66(6):2486.</citation>
    <PMID>15496178</PMID>
  </reference>
  <reference>
    <citation>Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. doi: 10.2215/CJN.00290109. Epub 2009 May 7.</citation>
    <PMID>19423571</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Ash Sehgal</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

